 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All evaluable participants, with prior PARP inhibitor therapy and chemotherapy, showed significant tumor shrinkage including one complete response Early data follows Phase 2 dose optimization change...

Allarity's Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP  Companion Diagnostic

Allarity Therapeutics files for $50M mixed shelf...

Allarity Therapeutics files for $50M mixed shelf

Allarity Therapeutics, Inc. (NASDAQ:ALLR  Get Free Report)s stock price shot up 4% during mid-day trading on Wednesday . The stock traded as high as $0.73 and last traded at $0.73...

Allarity Therapeutics (NASDAQ:ALLR) Shares Up 4%

Allarity will present on development of several drug-specific DRP companion diagnostics, and participate in a panel discussion with speakers from Merck and Roche BOSTON, October 2, 2023 Allarity...

Allarity Therapeutics to Present at Biomarkers Europe 2023

CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Allarity Therapeutics (NASDAQ:ALLR) is a biotechnology company focused on realizing true personalized cancer care by developing targeted cancer...

Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology

Thinking about buying stock in Allarity Therapeutics, Better Home & Finance Holding, Top KingWin, Axcella Health, or Metatron Apps? Thinking about buying stock in Allarity Therapeutics, Better Home & Finance Holding, Top KingWin, Axcella Health, or Metatron Apps? PR Newswire NEW...

Thinking about buying stock in Allarity Therapeutics, Better Home & Finance Holding, Top KingWin, Axcella Health, or Metatron Apps?

- The DRP-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to unselected patients BOSTON (August 30, 2023) Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq...

PLOS ONE Publishes Data on Allarity Therapeutics' DRP(R) Companion Diagnostic for Dovitinib

Allarity Therapeutics, Inc. (NASDAQ:ALLR  Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling...

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Large Increase in Short Interest

Thinking about buying stock in Oncolytics Biotech, INVO Bioscience, Troika Media Group, Allarity Therapeutics, or Barnes & Noble Education? Thinking about buying stock in Oncolytics Biotech, INVO Bioscience, Troika Media Group, Allarity Therapeutics, or Barnes & Noble Education? PR...

Thinking about buying stock in Oncolytics Biotech, INVO Bioscience, Troika Media Group, Allarity Therapeutics, or Barnes & Noble Education?

Allarity Therapeutics, Inc. (NASDAQ:ALLR  Get Free Report) saw a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 63,000 shares, an increase of 176.3% from the June 30th total of 22,800 shares. Based on an average trading volume of...

Short Interest in Allarity Therapeutics, Inc. (NASDAQ:ALLR) Rises By 176.3%

Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company was founded on April 4, 2021 and is headquartered in Boston, MA.

Market Cap	$2.04M
Volume (M)	1.24M
52-Wk High	$1,890.00
52-Wk Low	$0.401

Current Price	$0.5604
Prev Close	$0.488
Open	$0.49
Dividend Yield	0.00%
50-Day Moving Average	$0.5936
Beta	0.00
Avg. Volume	105,296.00
PE Ratio	0.00

52-Week High	$1,890.00
52-Week Low	$0.401
Market Capitalization	$2.04M
EPS	-$526.86
Price to Book	-0.40
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-0.22

ALLR Allarity Therapeutics Inc

About

Feed

News

Fundamentals